Effect of AKT1 (p. E17K) Hotspot Mutation on Malignant Tumorigenesis and Prognosis

被引:33
|
作者
Chen, Ying [1 ]
Huang, Lan [1 ]
Dong, Yongjian [1 ]
Tao, Changli [1 ]
Zhang, Rongxin [1 ]
Shao, Hongwei [1 ]
Shen, Han [1 ]
机构
[1] Guangdong Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Guangdong Prov Key Lab Biotechnol Drug Candidates, Guangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
AKT1; E17K; mutation; cancer; prognisis; PLECKSTRIN HOMOLOGY DOMAIN; KINASE INHIBITOR P27(KIP1); SQUAMOUS-CELL CARCINOMA; E3; LIGASE; ONCOGENIC MUTATION; PIK3CA MUTATIONS; HUMAN BREAST; AKT1(E17K) MUTATIONS; ACTIVATING MUTATION; INSULIN-RECEPTOR;
D O I
10.3389/fcell.2020.573599
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The substitution of the seventeenth amino acid glutamate by lysine in the homologous structural domain of the Akt1 gene pleckstrin is a somatic cellular mutation found in breast, colorectal, and ovarian cancers, named p. Glu17Lys or E17K. In recent years, a growing number of studies have suggested that this mutation may play a unique role in the development of tumors. In this review article, we describe how AKT1(E17K) mutations stimulate downstream signals that cause cells to emerge transformed; we explore the differential regulation and function of E17K in different physiological and pathological settings; and we also describe the phenomenon that E17K impedes tumor growth by interfering with growth-promoting and chemotherapy-resistant AKT1(low)QCC generation, an intriguing finding that mutants may prolong tumor patient survival by activating feedback mechanisms and disrupting transcription. This review is intended to provide a better understanding of the role of AKT1(E17K) in cancer and to inform the development of AKT1(E17K)-based antitumor strategies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma
    Zilberman, Dorit E.
    Cohen, Yoram
    Amariglio, Ninette
    Fridman, Edward
    Ramon, Jacob
    Rechavi, Gideon
    CANCER GENETICS AND CYTOGENETICS, 2009, 191 (01) : 34 - 37
  • [32] Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer
    Bose, Sminu
    Kalinsky, Kevin
    CLINICAL BREAST CANCER, 2021, 21 (03) : E150 - E153
  • [33] A functional and proteomics analysis of AKT1(E17K) in human mammary epithelial cells of luminal and myoepithelial cells of origin
    Salhia, Bodour
    DuQuette, Rachelle A.
    Van Cott, Courtney
    Tegler, Tony
    Polpitiya, Ashoka
    Petritis, Konstantinos
    Carpten, John
    CANCER RESEARCH, 2011, 71
  • [34] Sumoylation and the oncogenic E17K mutation affect AKT1 subcellular distribution and impact on Nanog-binding dynamics to chromatin in embryonic stem cells
    Francia, Marcos Gabriel
    Oses, Camila
    Garcia, Mora Renee
    Roberti, Sabrina Lorena
    Garcia, Mora Renee
    Cozza, Lucas Helio
    Diaz, Maria Candelaria
    Levi, Valeria
    Guberman, Alejandra Sonia
    JOURNAL OF STRUCTURAL BIOLOGY, 2023, 215 (02)
  • [35] Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations
    Zenz, T.
    Doehner, K.
    Denzel, T.
    Doehner, H.
    Stilgenbauer, S.
    Bullinger, L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 (05) : 742 - 743
  • [36] The Clinical and Functional Relevance of the Transforming AKT E17K Mutation in T-ALL
    Van der Zwet, Jordy C. G.
    Buijs-Gladdines, Jessica G. C. A. M.
    Mollova, Izabela
    Graus, Laura
    Bos, Frank L.
    Rios, Anne C.
    Meijerink, Jules P. P.
    BLOOD, 2019, 134
  • [37] Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas
    Williams, Sally R.
    Juratli, Tareq A.
    Castro, Brandyn A.
    Lazaro, Tyler T.
    Gill, Corey M.
    Nayyar, Naema
    Strickland, Matthew R.
    Babinski, Melanie
    Johnstone, Sarah E.
    Frosch, Matthew P.
    Silverman, Ian M.
    Ely, Heather A.
    Kaplan, Alexander B.
    D'Andrea, Megan R.
    Bihun, Ivanna V.
    Hoang, Kaitlin
    Batchelor, Emily
    Christiansen, Jason
    Cahill, Daniel P.
    Barker, Frederick G., II
    Brastianos, Priscilla K.
    JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2019, 80 (06) : 562 - 567
  • [38] Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations
    He, Yanli
    Zheng, Jine
    Hu, Yanjie
    Xiao, Hong
    Liu, Jun
    Li, Xiaoqing
    Du, Wen
    Chen, Xiangjun
    Hu, Yu
    Huang, Shiang
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (01) : 87 - 88
  • [39] Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
    Kim, M. S.
    Jeong, E. G.
    Yoo, N. J.
    Lee, S. H.
    BRITISH JOURNAL OF CANCER, 2008, 98 (09) : 1533 - 1535
  • [40] Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
    M S Kim
    E G Jeong
    N J Yoo
    S H Lee
    British Journal of Cancer, 2008, 98 : 1533 - 1535